{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:18:04Z","timestamp":1787840284725,"version":"build-2784847793"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"\n Background:<\/jats:title>\n This study aimed to compare the therapeutic efficacy and the side effects of different endostar administration methods in patients with advanced malignancy who underwent second-line chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n 98 patients with advanced malignancies were divided into 2 groups based on the delivery methods of endostar, including drip intravenous administration of endostar (DE) group and continuous intravenous administration of endostar (CE) group. Response rate (RR), disease control rate (DCR), and quality of life (QOL) of the patients were examined to evaluate the therapeutic efficacy, and toxicity reactions were analyzed to evaluate the adverse effects.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Compared with the DE group, the therapeutic efficacy of CE has been slightly improved, but the difference did not reach statistical significance (\n P<\/jats:italic>\n > 0.05). Additionally, no different incidence rate was observed in toxic reactions, including leukopenia, thrombocytopenia, nausea and vomiting, diarrhea, and hepatic function damage, between the DE and CE groups (\n P<\/jats:italic>\n > 0.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n In conclusion, no significant difference was observed between the traditional intravenous drip of endostar group and the intravenous drip followed by continuous pumping of endostar group in the patients with advanced malignancies.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijc.ijc_537_19","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T12:12:15Z","timestamp":1607602335000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Different administration methods of endostar combined with second-line chemotherapy in advanced malignancies"],"prefix":"10.4103","volume":"59","author":[{"given":"Shaoping","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunguo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongying People's Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"R1-20250603","first-page":"23","article-title":"Circular RNAs function as competing endogenous RNAs in multiple types of cancer","volume":"15","author":"Ji","year":"2018","journal-title":"Oncology Lett"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4103\/IJPC.IJPC_139_19","article-title":"Symptom Interference and Relation between the Domains of Quality of Life among Cancer Patients of Tertiary Care Hospital","volume":"25","author":"Nayak","year":"2019","journal-title":"Indian J Palliat Care"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2147\/OTT.S93629","article-title":"Intrahepatic cholangiocarcinoma: Current perspectives","volume":"10","author":"Buettner","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000464409","article-title":"Malignancy in solitary thyroid nodules: Evaluation of risk factors","volume":"40","author":"Uyar","year":"2017","journal-title":"Oncol Res Treat"},{"key":"R5-20250603","first-page":"2183","article-title":"Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs","volume":"16","author":"Jiang","year":"2018","journal-title":"Exp Ther Med"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"632","DOI":"10.14423\/SMJ.0000000000000709","article-title":"Emerging therapeutic strategies in breast cancer","volume":"110","author":"Cox","year":"2017","journal-title":"Southern Med J"},{"key":"R7-20250603","first-page":"4018","article-title":"Multimodal approach of advanced gastric cancer: Based therapeutic algorithm","volume":"20","author":"Berretta","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/14737140.2016.1170596","article-title":"Platinum-based chemotherapy in advanced non-small-cell lung cancer: Optimal number of treatment cycles","volume":"16","author":"Rossi","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3233\/CBM-170601","article-title":"The impact of chemotherapy-associated hemoglobin on prognosis of colorectal cancer patients receiving adjuvant chemotherapy","volume":"20","author":"Wei","year":"2017","journal-title":"Cancer Biomark"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"e0174658","DOI":"10.1371\/journal.pone.0174658","article-title":"Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K\/AKT\/mTOR pathway in prostate cancer","volume":"12","author":"Le","year":"2017","journal-title":"PLoS One"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10120-017-0707-8","article-title":"Second-line chemotherapy for patients with advanced gastric cancer","volume":"20","author":"Takahari","year":"2017","journal-title":"Gastric Cancer"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: Alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/mc.22718","article-title":"Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo","volume":"57","author":"Zhang","year":"2018","journal-title":"Mol Carcinog"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1053\/j.seminoncol.2017.07.004","article-title":"Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis","volume":"44","author":"Chebib","year":"2017","journal-title":"Semina Oncol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"e12750","DOI":"10.1097\/MD.0000000000012750","article-title":"Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors","volume":"97","author":"Cheng","year":"2018","journal-title":"Medicine"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/1759-7714.12891","article-title":"Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma","volume":"10","author":"Wang","year":"2019","journal-title":"Thorac Cancer"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PPO.0000000000000200","article-title":"Angiogenesis in colorectal cancer: Antibodies","volume":"22","author":"Chan","year":"2016","journal-title":"Cancer J"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41389-018-0102-2","article-title":"The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer","volume":"7","author":"Xu","year":"2018","journal-title":"Oncogenesis"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"15837","DOI":"10.1038\/s41598-018-34030-5","article-title":"Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model","volume":"8","author":"Jin","year":"2018","journal-title":"Sci Rep"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1073\/pnas.0730882100","article-title":"Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins","volume":"100","author":"Sudhakar","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-20250603","first-page":"294","article-title":"[Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens]","volume":"38","author":"Kong","year":"2016","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1002\/cam4.941","article-title":"Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma","volume":"5","author":"Pericay","year":"2016","journal-title":"Cancer Med"},{"key":"R23-20250603","first-page":"618","article-title":"[Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer]","volume":"35","author":"Wang","year":"2013","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"Supplement","key":"R24-20250603","first-page":"S1148","article-title":"Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer","volume":"14","author":"Yang","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.2147\/IJN.S82029","article-title":"GX1-conjugated poly (lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment","volume":"10","author":"Du","year":"2015","journal-title":"Int J Nanomed"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"e11822","DOI":"10.1097\/MD.0000000000011822","article-title":"Influence of different drug delivery methods for Endostar combined with a gemcitabine\/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: A retrospective observational study","volume":"97","author":"Yao","year":"2018","journal-title":"Medicine"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"70788","DOI":"10.18632\/oncotarget.19989","article-title":"Clinical efficacy of endostar combined with chemotherapy in the treatment of peritoneal carcinomatosis in gastric cancer: Results from a retrospective study","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11136-016-1429-9","article-title":"Assessment of quality of life in advanced, metastatic prostate cancer: An overview of randomized phase III trials","volume":"26","author":"Adamowicz","year":"2017","journal-title":"Qual Life Res"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/07357907.2018.1515954","article-title":"Toxicity and efficacy of sequential chemotherapy in patients with p-stage I non-small cell lung cancer that recurring during postoperative tegafur-uracil adjuvant chemotherapy","volume":"36","author":"Kashiwabara","year":"2018","journal-title":"Cancer Invest"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1186\/s12885-018-4738-2","article-title":"Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma","volume":"18","author":"Qin","year":"2018","journal-title":"BMC Cancer"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/cas.13392","article-title":"Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models","volume":"108","author":"Ito","year":"2017","journal-title":"Cancer Sci"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_537_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:19:23Z","timestamp":1787836763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_537_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_537_19","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]},"assertion":[{"value":"2019-06-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}